{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T13:38:30Z","timestamp":1778852310493,"version":"3.51.4"},"reference-count":49,"publisher":"Public Library of Science (PLoS)","issue":"3","license":[{"start":{"date-parts":[[2011,3,22]],"date-time":"2011-03-22T00:00:00Z","timestamp":1300752000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0018049","type":"journal-article","created":{"date-parts":[[2011,3,22]],"date-time":"2011-03-22T20:55:11Z","timestamp":1300827311000},"page":"e18049","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":18,"title":["The Ras Antagonist, Farnesylthiosalicylic Acid (FTS), Decreases Fibrosis and Improves Muscle Strength in dy2J\/dy2J Mouse Model of Muscular Dystrophy"],"prefix":"10.1371","volume":"6","author":[{"given":"Yoram","family":"Nevo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shlomit","family":"Aga-Mizrachi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edva","family":"Elmakayes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nurit","family":"Yanay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keren","family":"Ettinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moran","family":"Elbaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zivia","family":"Brunschwig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oshrat","family":"Dadush","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Galit","family":"Elad-Sfadia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roni","family":"Haklai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoel","family":"Kloog","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joab","family":"Chapman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shimon","family":"Reif","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2011,3,22]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.nmd.2004.06.009","article-title":"The congenital muscular dystrophies in 2004: a century of exciting progress.","volume":"14","author":"F Muntoni","year":"2004","journal-title":"Neuromuscul Disord"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1007\/s00018-004-4510-4","article-title":"Congenital muscular dystrophy: molecular and cellular aspects.","volume":"62","author":"C Jimenez-Mallebrera","year":"2005","journal-title":"Cell Mol Life Sci"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1038\/ng1194-297","article-title":"Murine muscular dystrophy caused by a mutation in the laminin alpha 2 (Lama2) gene.","volume":"8","author":"H Xu","year":"1994","journal-title":"Nat Genet"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S0960-8966(99)00056-5","article-title":"Identification of homozygous and heterozygous dy2J mice by PCR.","volume":"10","author":"JT Vilquin","year":"2000","journal-title":"Neuromuscul Disord"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1016\/S0960-9822(00)80056-1","article-title":"The laminin alpha2 expressed by dystrophic dy(2J) mice is defective in its ability to form polymers.","volume":"9","author":"H Colognato","year":"1999","journal-title":"Curr Biol"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s12031-007-9023-9","article-title":"Animal models for genetic neuromuscular diseases.","volume":"34","author":"M Vainzof","year":"2008","journal-title":"J Mol Neurosci"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1177\/088307389501000610","article-title":"Demyelinating peripheral neuropathy in merosin-deficient congenital muscular dystrophy.","volume":"10","author":"Z Shorer","year":"1995","journal-title":"J Child Neurol"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1002\/(SICI)1097-0029(20000201\/15)48:3\/4<181::AID-JEMT6>3.0.CO;2-Q","article-title":"Merosin and congenital muscular dystrophy.","volume":"48","author":"Y Miyagoe-Suzuki","year":"2000","journal-title":"Microsc Res Tech"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.spen.2006.06.003","article-title":"Congenital muscular dystrophies and the extracellular matrix.","volume":"13","author":"J Schessl","year":"2006","journal-title":"Semin Pediatr Neurol"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1096\/fasebj.7.9.8330683","article-title":"Emerging concepts in the Ras superfamily of GTP-binding proteins.","volume":"7","author":"GM Bokoch","year":"1993","journal-title":"FASEB J"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0955-0674(99)00071-X","article-title":"The Ras branch of small GTPases: Ras family members don&apos;t fall far from the tree.","volume":"12","author":"GW Reuther","year":"2000","journal-title":"Curr Opin Cell Biol"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1126\/science.277.5324.333","article-title":"The Ras-RasGAP complex: structural basis for GTPase activation and its loss in oncogenic Ras mutants.","volume":"277","author":"K Scheffzek","year":"1997","journal-title":"Science"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.jneuroim.2005.07.008","article-title":"Inhibition of Ras attenuates the course of experimental autoimmune neuritis.","volume":"168","author":"M Kafri","year":"2005","journal-title":"J Neuroimmunol"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1097\/01.ASN.0000057543.55318.8B","article-title":"Ras antagonist farnesylthiosalicylic acid (FTS) reduces glomerular cellular proliferation and macrophage number in rat thy-1 nephritis.","volume":"14","author":"HC Clarke","year":"2003","journal-title":"J Am Soc Nephrol"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1046\/j.1365-2249.2001.01674.x","article-title":"Treatment of MRL\/lpr mice, a genetic autoimmune model, with the Ras inhibitor, farnesylthiosalicylate (FTS).","volume":"126","author":"A Katzav","year":"2001","journal-title":"Clin Exp Immunol"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1038\/sj.leu.2401367","article-title":"Modulation of the immune response and tumor growth by activated Ras.","volume":"13","author":"S Weijzen","year":"1999","journal-title":"Leukemia"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1021\/bi972032d","article-title":"Dislodgment and accelerated degradation of Ras.","volume":"37","author":"R Haklai","year":"1998","journal-title":"Biochemistry"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"22263","DOI":"10.1074\/jbc.270.38.22263","article-title":"Selective inhibition of Ras-dependent cell growth by farnesylthiosalisylic acid.","volume":"270","author":"M Marom","year":"1995","journal-title":"J Biol Chem"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/S1357-4310(00)01789-5","article-title":"RAS inhibitors: potential for cancer therapeutics.","volume":"6","author":"Y Kloog","year":"2000","journal-title":"Mol Med Today"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1097\/00062752-200207000-00008","article-title":"Ras processing as a therapeutic target in hematologic malignancies.","volume":"9","author":"DT Le","year":"2002","journal-title":"Curr Opin Hematol"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1002\/(SICI)1097-0215(19990315)80:6<911::AID-IJC18>3.0.CO;2-4","article-title":"Growth inhibition of ras-dependent tumors in nude mice by a potent ras-dislodging antagonist.","volume":"80","author":"Y Egozi","year":"1999","journal-title":"Int J Cancer"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.jhep.2004.04.010","article-title":"Treatment of thioacetamide-induced liver cirrhosis by the Ras antagonist, farnesylthiosalicylic acid.","volume":"41","author":"S Reif","year":"2004","journal-title":"J Hepatol"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/S0168-8278(99)80318-3","article-title":"The Ras antagonist, farnesylthiosalicylic acid (FTS), inhibits experimentally-induced liver cirrhosis in rats.","volume":"31","author":"S Reif","year":"1999","journal-title":"J Hepatol"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1021\/jm00008a004","article-title":"Farnesyl derivatives of rigid carboxylic acids-inhibitors of ras-dependent cell growth.","volume":"38","author":"D Marciano","year":"1995","journal-title":"J Med Chem"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.nmd.2010.02.002","article-title":"Improved muscle strength and mobility in the dy(2J)\/dy(2J) mouse with merosin deficient congenital muscular dystrophy treated with Glatiramer acetate.","volume":"20","author":"O Dadush","year":"2010","journal-title":"Neuromuscul Disord"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"37169","DOI":"10.1074\/jbc.M205698200","article-title":"Galectin-1 augments Ras activation and diverts Ras signals to Raf-1 at the expense of phosphoinositide 3-kinase.","volume":"277","author":"G Elad-Sfadia","year":"2002","journal-title":"J Biol Chem"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/0006-291X(88)90215-X","article-title":"Ras oncogene mediated induction of a 92 kDa metalloproteinase; strong correlation with the malignant phenotype.","volume":"154","author":"M Ballin","year":"1988","journal-title":"Biochem Biophys Res Commun"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.bbadis.2006.09.006","article-title":"Congenital muscular dystrophies: new aspects of an expanding group of disorders.","volume":"1772","author":"MT Lisi","year":"2007","journal-title":"Biochim Biophys Acta"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/nrm2438","article-title":"Ras oncogenes: split personalities.","volume":"9","author":"AE Karnoub","year":"2008","journal-title":"Nat Rev Mol Cell Biol"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1126\/science.1134727","article-title":"Signal transduction. Prelude to an anniversary for the RAS oncogene.","volume":"314","author":"J Downward","year":"2006","journal-title":"Science"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/S0079-6603(02)71047-7","article-title":"A growing family of guanine nucleotide exchange factors is responsible for activation of Ras-family GTPases.","volume":"71","author":"LA Quilliam","year":"2002","journal-title":"Prog Nucleic Acid Res Mol Biol"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"31","DOI":"10.2174\/157489208783478702","article-title":"Inhibitors of chronically active ras: potential for treatment of human malignancies.","volume":"3","author":"R Blum","year":"2008","journal-title":"Recent Pat Anticancer Drug Discov"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1517\/13543784.8.12.2121","article-title":"Concepts in Ras-directed therapy.","volume":"8","author":"Y Kloog","year":"1999","journal-title":"Expert Opin Investig Drugs"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/s0960-8966(02)00266-3","article-title":"Laminin alpha2 deficiency and muscular dystrophy; genotype-phenotype correlation in mutant mice.","volume":"13","author":"LT Guo","year":"2003","journal-title":"Neuromuscul Disord"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/S0167-4889(99)00144-5","article-title":"Targeting of K-Ras 4B by S-trans,trans-farnesyl thiosalicylic acid.","volume":"1452","author":"G Elad","year":"1999","journal-title":"Biochim Biophys Acta"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1002\/mus.10529","article-title":"Matrix metalloproteinases and skeletal muscle: a brief review.","volume":"29","author":"E Carmeli","year":"2004","journal-title":"Muscle Nerve"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1002\/bdrc.20061","article-title":"Matrix metalloproteinases and cellular motility in development and disease.","volume":"78","author":"MN VanSaun","year":"2006","journal-title":"Birth Defects Res C Embryo Today"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1212\/WNL.54.1.65","article-title":"Expression of matrix metalloproteinases in the muscle of patients with inflammatory myopathies.","volume":"54","author":"YC Choi","year":"2000","journal-title":"Neurology"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/bies.950140705","article-title":"The matrix-degrading metalloproteinases.","volume":"14","author":"LM Matrisian","year":"1992","journal-title":"Bioessays"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1002\/mus.20970","article-title":"Pattern of metalloprotease activity and myofiber regeneration in skeletal muscles of mdx mice.","volume":"37","author":"C Bani","year":"2008","journal-title":"Muscle Nerve"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1006\/bbrc.2000.3735","article-title":"Unusual laminin alpha2 processing in myoblasts from a patient with a novel variant of congenital muscular dystrophy.","volume":"277","author":"G Lattanzi","year":"2000","journal-title":"Biochem Biophys Res Commun"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1006\/dbio.1998.9107","article-title":"Expression of matrix metalloproteinases 2 and 9 in regenerating skeletal muscle: a study in experimentally injured and mdx muscles.","volume":"205","author":"S Kherif","year":"1999","journal-title":"Dev Biol"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1034\/j.1600-0404.2002.1o104.x","article-title":"Matrix metalloproteinases in inflammatory myopathies: enhanced immunoreactivity near atrophic myofibers.","volume":"105","author":"BG Schoser","year":"2002","journal-title":"Acta Neurol Scand"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1093\/hmg\/ddp191","article-title":"Matrix metalloproteinase-9 inhibition ameliorates pathogenesis and improves skeletal muscle regeneration in muscular dystrophy.","volume":"18","author":"H Li","year":"2009","journal-title":"Hum Mol Genet"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"333","DOI":"10.2174\/138161207779313551","article-title":"Matrix metalloproteinases as valid clinical targets.","volume":"13","author":"B Fingleton","year":"2007","journal-title":"Curr Pharm Des"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1111\/j.1471-4159.2007.05020.x","article-title":"Over-expression of GTP-binding proteins and GTPase activity in mouse astrocyte membranes in response to Theiler&apos;s murine encephalomyelitis virus infection.","volume":"104","author":"N Rubio","year":"2008","journal-title":"J Neurochem"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1046\/j.1471-4159.2000.0742288.x","article-title":"Expression of a dominant-negative mutant of p21(ras) inhibits induction of nitric oxide synthase and activation of nuclear factor-kappaB in primary astrocytes.","volume":"74","author":"K Pahan","year":"2000","journal-title":"J Neurochem"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1002\/mus.21706","article-title":"Fibrosis inhibition and muscle histopathology improvement in laminin-alpha2-deficient mice.","volume":"42","author":"Y Nevo","year":"2010","journal-title":"Muscle Nerve"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/nm1536","article-title":"Angiotensin II type 1 receptor blockade attenuates TGF-beta-induced failure of muscle regeneration in multiple myopathic states.","volume":"13","author":"RD Cohn","year":"2007","journal-title":"Nat Med"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0018049","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,5]],"date-time":"2024-04-05T10:37:38Z","timestamp":1712313458000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0018049"}},"subtitle":[],"editor":[{"given":"Todd","family":"Lamitina","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2011,3,22]]},"references-count":49,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2011,3,22]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0018049","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,3,22]]}}}